Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients

Haematologica

Volumn 85, Issue 9, 2000, Pages 926-929

  Zinzani, P L ^a   Bendandi, M ^a   Stefoni, V ^a   Albertini, P ^a   Gherlinzoni, F ^a   Tani, M ^a   Piccaluga, P P ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Gemcitabine; Hodgkin's disease; Pretreated patients

Indexed keywords

BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; ALOPECIA; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RETREATMENT; THROMBOCYTOPENIA;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RECURRENCE; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033782490     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hodgkin's disease
2. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease
3. EPIC: An effective low toxicity regimen for relapsing lymphoma
4. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease
5. CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease
6. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate
7. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease
8. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse
9. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease
10. Hodgkin's disease: The role of bone marrow transplantation
11. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease
12. Vinorelbine: A new promising drug in Hodgkin's disease
13. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma
14. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines
15. Gemcitabine is active in relapsed Hodgkin's disease
16. Phase II study of gemcitabine in patients with multiple pretreated Hodgkin's disease. Results of a multicenter study
17. Gemcitabine: Preclinical pharmacology and mechanisms of action
18. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review
19. Promising new therapies in the treatment of advanced ovarian cancer
20. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: A review
21. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells
22. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors
23. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting
24. Toxicity and response criteria of the Eastern Cooperative Oncology Group
25. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's. Lymphoma Study Group
26. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
27. Twenty years of MOPP therapy for Hodgkin's disease
28. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
29. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma
30. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients
31. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients